Eliquis 2.5 mg (Apixaban)

Product Overview

Eliquis 2.5 mg is a prescription anticoagulant medication manufactured by Bristol‑Myers Squibb India Pvt. Ltd. It is formulated to reduce the risk of blood clot formation in patients at increased risk of stroke, deep vein thrombosis, and pulmonary embolism. The product is supplied in strip packaging containing either 10 or 20 tablets, with available pack sizes of 30, 60, or 90 tablets. Each tablet delivers a precise dose of apixaban, the active ingredient that provides consistent anticoagulation without the need for routine laboratory monitoring. This medication is indicated for the prevention of blood clots in adults who have a medical condition that increases clotting risk, such as atrial fibrillation, recent orthopedic surgery, or a history of venous thromboembolism. The packaging is designed for convenience, allowing patients to carry a portable supply while maintaining product integrity.

What is Eliquis 2.5 mg

Eliquis 2.5 mg contains the active ingredient apixaban, a selective inhibitor of factor Xa, which plays a central role in the coagulation cascade. By binding to factor Xa, apixaban prevents the conversion of prothrombin to thrombin, thereby reducing the generation of fibrin clots. This mechanism distinguishes Eliquis from older anticoagulants that require vitamin K antagonism or heparinoid activity. The drug is administered orally, is rapidly absorbed, and exhibits a low potential for drug‑drug interactions. Its pharmacokinetic profile supports twice‑daily dosing, providing steady plasma concentrations that sustain anticoagulant effect throughout the day. Clinical studies have demonstrated that apixaban offers comparable or superior protection against stroke and systemic embolism when compared with warfarin in patients with non‑valvular atrial fibrillation. For detailed prescribing information, see the FDA prescribing information and learn more about factor Xa inhibition at the National Institutes of Health.

Uses and Benefits

The primary use of Eliquis 2.5 mg is the prevention of blood clots that can lead to serious cardiovascular events. It is approved for the reduction of stroke risk in patients with non‑valvular atrial fibrillation, for the treatment and secondary prevention of deep vein thrombosis, and for the management of pulmonary embolism. In addition, the medication is prescribed to lower the risk of clot formation after hip or knee replacement surgery. Patients who take Eliquis often experience a lower incidence of major bleeding compared with traditional vitamin K antagonists, and they do not require frequent blood tests to adjust dosage. The convenience of a fixed‑dose oral tablet, combined with a favorable safety profile, makes Eliquis a preferred choice for many clinicians seeking reliable clot prevention. More patient‑focused details are available at MedlinePlus.

How It Works

Eliquis works by selectively inhibiting factor Xa, an enzyme that catalyzes the conversion of prothrombin to thrombin. Thrombin is a key enzyme that converts fibrinogen into fibrin, the insoluble protein strands that form a stable clot. By blocking factor Xa, apixaban reduces thrombin generation, which in turn limits fibrin formation and stabilizes the clotting process. This inhibition occurs rapidly after ingestion, with peak plasma concentrations reached within a few hours. The drug is eliminated primarily through hepatic metabolism by the cytochrome P450 enzymes CYP3A4 and CYP2J2, and renal excretion accounts for a modest portion of clearance. Because apixaban does not significantly affect platelet function, its antithrombotic effect is primarily directed at the coagulation cascade rather than the cellular components of blood.

Dosage Guidelines

The recommended dosing regimen for clot prevention typically involves taking one 2.5 mg tablet twice daily, with or without food, as directed by a healthcare professional. The exact schedule may vary based on the patient’s renal function, body weight, and the specific clinical indication. For patients with severe renal impairment, a reduced frequency of dosing may be advised. It is important to swallow the tablet whole and not to crush or split it, as the dose is calibrated for optimal therapeutic effect. If a dose is missed, the patient should take it as soon as remembered unless it is close to the time of the next scheduled dose; in that case, the missed dose should be skipped and the regular dosing schedule resumed. Consistency in timing helps maintain steady drug levels and maximizes efficacy.

Side Effects

Like all medications, Eliquis 2.5 mg can cause adverse effects. The most commonly reported side effects include mild bleeding, easy bruising, and skin rash. Some patients may experience nausea, fatigue, or headache. Although serious bleeding is uncommon, it can manifest as gastrointestinal hemorrhage, blood in the urine, or unusually heavy menstrual periods. Rarely, allergic reactions such as swelling of the face or throat may occur. Patients should seek immediate medical attention if they notice signs of significant bleeding, such as black stools, severe abdominal pain, or prolonged nosebleeds. Reporting any unexpected symptoms to a physician ensures timely evaluation and management.

Warnings and Precautions

Eliquis should not be used by individuals with active bleeding disorders, severe liver disease, or those undergoing scheduled surgery without prior medical assessment. Concomitant use of other anticoagulants, certain antiplatelet agents, or drugs that strongly inhibit or induce CYP3A4 may increase the risk of bleeding or reduce therapeutic effect. Pregnant or breastfeeding women should consult their healthcare provider before initiating therapy, as the safety of apixaban during these periods has not been fully established. Patients scheduled for invasive procedures should inform their surgeon of all medications, including over‑the‑counter supplements, to determine the appropriate timing for discontinuation. Finally, abrupt cessation of the medication can precipitate a rebound hypercoagulable state, so any changes should be made under professional guidance. Additional patient counseling resources can be found at the NIH website.

Frequently Asked Questions

Can Eliquis be taken with food?

Yes, the tablet may be taken with or without food. Taking it with a meal can help reduce stomach discomfort, but it does not affect the drug’s absorption or effectiveness.

Is dose adjustment needed for elderly patients?

Older adults may require a careful evaluation of kidney function before starting therapy, as renal clearance can be reduced with age. However, the standard 2.5 mg twice‑daily dose is generally appropriate unless laboratory results indicate a need for modification.

What should I do if I experience bleeding?

If you notice signs of bleeding such as unusual bruising, blood in urine or stool, or prolonged nosebleeds, contact your healthcare provider promptly. For minor bleeding, apply pressure and monitor the situation; severe bleeding requires immediate medical attention.

Can I switch from warfarin to Eliquis?

Transitioning from warfarin to Eliquis should be done under medical supervision. Your doctor will calculate an appropriate overlap period to maintain anticoagulation coverage and ensure no gap in protection against clot formation.

How long will I need to take this medication?

The duration of treatment depends on the underlying condition and individual risk factors. Some patients may use Eliquis for a limited period, while others may require long‑term therapy. Your physician will determine the appropriate length based on clinical assessment.